hat
LGD-4033, yon roman nonsteroidal, oral selektif reseptè modulator modèn, mare reseptè a Androjenèn ak afinite segondè, epi selektivite. Li demontre aktivite anabolik nan misk, anti-resorptif ak aktivite anabolik nan zo ak yon selektivite gaya pou misk ak zo kont pwostat ak glann sebase. LGD-4033 dènyèman te konplete yon Faz I miltip moute dòz etid nan volontè sante yo. Sa a randomized, double-avèg, plasebo-kontwole Faz mwen etid etabli sekirite a ak tolerans jiska dòz 22 mg chak jou.
eng
LGD-4033, a novel nonsteroidal, oral selective androgen receptor modulator, binds to the androgen receptor with high affinity and selectivity. It demonstrates anabolic activity in muscles, anti-resorptive and anabolic activity in bones and a robust selectivity for muscle and bone versus prostate and sebaceous glands. LGD-4033 has recently completed a Phase I Multiple Ascending Dose study in healthy volunteers. This randomized, double-blind, placebo-controlled Phase I study established the safety and tolerability up to doses of 22 mg per day.